Metabolic Dysfunction-associated Steatohepatitis (MASH) – Epidemiology Forecast – 2034
Description
Key Highlights
DelveInsight’s analyst projects that in 2024, the 7MM reported approximately 30 million prevalent and nearly 8 million diagnosed prevalent cases of MASH, reflecting a significant disease burden.
In 2024, the US reported the highest number of diagnosed prevalent cases of MASH among the 7MM, with approximately 5 million cases.
In 2024, within EU4 and the UK, Germany accounted for the highest share of diagnosed prevalent MASH cases, representing 28% of the total, followed by Italy with 22%.
In 2024, France reported the highest number of MASH cases at the F1 stage, with nearly 200 thousand cases, while the F4 stage had the lowest, with approximately 30 thousand cases.
In 2024, MASH affected more males than females in Spain, with the number of cases in both sexes projected to increase by 2034.
In 2024, Japan had approximately 680 thousand diagnosed prevalent cases of MASH, a figure expected to grow by 2034.
DelveInsight’s “Metabolic Dysfunction-associated Steatohepatitis (MASH) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of MASH, historical and forecasted epidemiology of MASH in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Metabolic Dysfunction-associated Steatohepatitis (MASH) Understanding
MASH overview
MASH, formerly known as NASH (non-alcoholic steatohepatitis), is defined as itch lasting longer than six weeks and is a complex condition that significantly affects quality of life. It may arise from dermatological, systemic, infectious, or neurological causes, with inflammatory and neuropathic mechanisms often involved. Triggers include liver and kidney disorders, medications, parasitic infestations, and skin infections. The condition may present as a “pure” itch or with burning or stinging sensations, with symptoms influenced by environmental factors. While the mechanisms remain unclear, pathways such as NK1R, JAK, and TRP ion channels are implicated, offering potential therapeutic targets.
MASH diagnosis
Diagnosing MASH requires a comprehensive and systematic approach due to its wide range of potential causes. Initial evaluation includes a detailed clinical history and physical examination to identify visible skin changes or systemic signs. Laboratory tests are often conducted to assess liver, kidney, and thyroid function, as well as iron levels and markers of inflammation. Additional investigations, such as skin scrapings or biopsies, may be needed to rule out infections or malignancies. In cases with no clear dermatological findings, neurological assessments, including nerve conduction studies or imaging, may be warranted to identify neuropathic causes. Despite available tools, diagnosis is often delayed due to the condition’s complexity and lack of standardized protocols.
Further details related to diagnosis are provided in the report…
Metabolic Dysfunction-associated Steatohepatitis (MASH) Epidemiology
For the purpose of designing the patient-based model for MASH, the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of MASH, total diagnosed prevalent cases of MASH, gender-specific diagnosed prevalent cases of MASH, and severity-specific diagnosed prevalent cases of MASH in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.
According to DelveInsight’s estimates, in 2024, there were approximately 8 million diagnosed prevalent cases of MASH in the 7MM.
In 2024, the US accounted for approximately 58% of diagnosed prevalent cases of MASH across the 7MM. DelveInsight forecasts a rise in this figure by 2034, reflecting the growing burden of the disease.
The rise in diagnosed prevalent cases of MASH in the US is driven by greater use of imaging to identify Non-alcoholic Fatty Liver Disease (NAFLD) and increased liver biopsies among individuals with elevated liver enzymes, clinical suspicion, or tertiary care referrals. As MASH requires histologic confirmation, liver biopsy remains the diagnostic gold standard.
In 2024, Germany reported the highest number of diagnosed prevalent MASH cases among EU4 and the UK, with approximately 795 thousand cases, while Spain had the lowest, with around 350 thousand cases.
In terms of gender-specific diagnosed prevalent cases of MASH, France reported more female cases than male cases in 2024, with females accounting for approximately 54% of the total diagnosed cases. Both male and female case numbers are expected to rise by 2034.
Regarding severity-specific diagnosed prevalent cases of MASH, the UK reported nearly 115 thousand, 180 thousand, 100 thousand, 60 thousand, and 40 thousand cases in the F0, F1, F2, F3, and F4 stage in 2024. These numbers are expected to grow by 2034.
In 2024, Japan reported the highest number of MASH cases at the F1 stage, with approximately 245 thousand cases, and this number is expected to rise by 2034.
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.
DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Department of Hospital Medicine, US, University of Florida Gainesville, US, University of Colorado Anschutz Medical Campus, US, Charité University Medicine Berlin, Germany, Hopital Beaujon, France, University of Turin, Italy, Marqués de Valdecilla University Hospital, Spain, Newcastle University, UK, Kobe Asahi Hospital, Japan, The Japanese Society of Gastroenterology, Japan, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
As per the KOLs from Germany, disease recognition using the clinical network and analysis of MASLD are insufficient, possibly associated with the asymptomatic phenotype of early and compensated disease stages.
Scope of the Report
The report covers a segment of executive summary, descriptive overview of MASH, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
A detailed review of current challenges in establishing the diagnosis.
Metabolic Dysfunction-associated Steatohepatitis (MASH) Report Insights
Patient Population
Country-wise Epidemiology Distribution
Total Prevalent Cases of MASH
Total Diagnosed Prevalent Cases of MASH
Gender-specific Diagnosed Prevalent Cases of MASH
Severity-specific Diagnosed Prevalent Cases of MASH
Metabolic Dysfunction-associated Steatohepatitis (MASH) Report Key Strengths
10 years Forecast
The 7MM Coverage
MASH Epidemiology Segmentation
Metabolic Dysfunction-associated Steatohepatitis (MASH) Report Assessment
Current Diagnostic Practices Patient Segmentation
Epidemiology Insights
What are the disease risk, burdens, and unmet needs of MASH? What will be the growth opportunities across the 7MM concerning the patient population of MASH?
What is the historical and forecasted MASH patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
Why is the diagnosed prevalent cases of MASH in Japan lower than the US?
Which country has a high patient share for MASH?
Reasons to Buy
Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the MASH prevalent cases in varying geographies over the coming years, along with diagnosed prevalent cases of MASH.
A detailed overview of gender and severity-specific diagnosed prevalent cases of MASH.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Frequently Asked Questions
1. What is the forecast period covered in the report?
The MASH epidemiology report for the 7MM covers the forecast period from 2025 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.
2. Out of all EU4 countries and the UK, which country had the highest population of MASH cases in 2024?
The highest cases of MASH was found in the Germany among EU4 and the UK in 2024.
3. How is epidemiological data collected and analyzed for forecasting purposes?
Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.
4. Out of all 7MM countries, which country had the highest population of MASH cases in 2024?
The highest cases of MASH were found in the US among the 7MM in 2024.
DelveInsight’s analyst projects that in 2024, the 7MM reported approximately 30 million prevalent and nearly 8 million diagnosed prevalent cases of MASH, reflecting a significant disease burden.
In 2024, the US reported the highest number of diagnosed prevalent cases of MASH among the 7MM, with approximately 5 million cases.
In 2024, within EU4 and the UK, Germany accounted for the highest share of diagnosed prevalent MASH cases, representing 28% of the total, followed by Italy with 22%.
In 2024, France reported the highest number of MASH cases at the F1 stage, with nearly 200 thousand cases, while the F4 stage had the lowest, with approximately 30 thousand cases.
In 2024, MASH affected more males than females in Spain, with the number of cases in both sexes projected to increase by 2034.
In 2024, Japan had approximately 680 thousand diagnosed prevalent cases of MASH, a figure expected to grow by 2034.
DelveInsight’s “Metabolic Dysfunction-associated Steatohepatitis (MASH) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of MASH, historical and forecasted epidemiology of MASH in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Metabolic Dysfunction-associated Steatohepatitis (MASH) Understanding
MASH overview
MASH, formerly known as NASH (non-alcoholic steatohepatitis), is defined as itch lasting longer than six weeks and is a complex condition that significantly affects quality of life. It may arise from dermatological, systemic, infectious, or neurological causes, with inflammatory and neuropathic mechanisms often involved. Triggers include liver and kidney disorders, medications, parasitic infestations, and skin infections. The condition may present as a “pure” itch or with burning or stinging sensations, with symptoms influenced by environmental factors. While the mechanisms remain unclear, pathways such as NK1R, JAK, and TRP ion channels are implicated, offering potential therapeutic targets.
MASH diagnosis
Diagnosing MASH requires a comprehensive and systematic approach due to its wide range of potential causes. Initial evaluation includes a detailed clinical history and physical examination to identify visible skin changes or systemic signs. Laboratory tests are often conducted to assess liver, kidney, and thyroid function, as well as iron levels and markers of inflammation. Additional investigations, such as skin scrapings or biopsies, may be needed to rule out infections or malignancies. In cases with no clear dermatological findings, neurological assessments, including nerve conduction studies or imaging, may be warranted to identify neuropathic causes. Despite available tools, diagnosis is often delayed due to the condition’s complexity and lack of standardized protocols.
Further details related to diagnosis are provided in the report…
Metabolic Dysfunction-associated Steatohepatitis (MASH) Epidemiology
For the purpose of designing the patient-based model for MASH, the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of MASH, total diagnosed prevalent cases of MASH, gender-specific diagnosed prevalent cases of MASH, and severity-specific diagnosed prevalent cases of MASH in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.
According to DelveInsight’s estimates, in 2024, there were approximately 8 million diagnosed prevalent cases of MASH in the 7MM.
In 2024, the US accounted for approximately 58% of diagnosed prevalent cases of MASH across the 7MM. DelveInsight forecasts a rise in this figure by 2034, reflecting the growing burden of the disease.
The rise in diagnosed prevalent cases of MASH in the US is driven by greater use of imaging to identify Non-alcoholic Fatty Liver Disease (NAFLD) and increased liver biopsies among individuals with elevated liver enzymes, clinical suspicion, or tertiary care referrals. As MASH requires histologic confirmation, liver biopsy remains the diagnostic gold standard.
In 2024, Germany reported the highest number of diagnosed prevalent MASH cases among EU4 and the UK, with approximately 795 thousand cases, while Spain had the lowest, with around 350 thousand cases.
In terms of gender-specific diagnosed prevalent cases of MASH, France reported more female cases than male cases in 2024, with females accounting for approximately 54% of the total diagnosed cases. Both male and female case numbers are expected to rise by 2034.
Regarding severity-specific diagnosed prevalent cases of MASH, the UK reported nearly 115 thousand, 180 thousand, 100 thousand, 60 thousand, and 40 thousand cases in the F0, F1, F2, F3, and F4 stage in 2024. These numbers are expected to grow by 2034.
In 2024, Japan reported the highest number of MASH cases at the F1 stage, with approximately 245 thousand cases, and this number is expected to rise by 2034.
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.
DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Department of Hospital Medicine, US, University of Florida Gainesville, US, University of Colorado Anschutz Medical Campus, US, Charité University Medicine Berlin, Germany, Hopital Beaujon, France, University of Turin, Italy, Marqués de Valdecilla University Hospital, Spain, Newcastle University, UK, Kobe Asahi Hospital, Japan, The Japanese Society of Gastroenterology, Japan, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
As per the KOLs from Germany, disease recognition using the clinical network and analysis of MASLD are insufficient, possibly associated with the asymptomatic phenotype of early and compensated disease stages.
Scope of the Report
The report covers a segment of executive summary, descriptive overview of MASH, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
A detailed review of current challenges in establishing the diagnosis.
Metabolic Dysfunction-associated Steatohepatitis (MASH) Report Insights
Patient Population
Country-wise Epidemiology Distribution
Total Prevalent Cases of MASH
Total Diagnosed Prevalent Cases of MASH
Gender-specific Diagnosed Prevalent Cases of MASH
Severity-specific Diagnosed Prevalent Cases of MASH
Metabolic Dysfunction-associated Steatohepatitis (MASH) Report Key Strengths
10 years Forecast
The 7MM Coverage
MASH Epidemiology Segmentation
Metabolic Dysfunction-associated Steatohepatitis (MASH) Report Assessment
Current Diagnostic Practices Patient Segmentation
Epidemiology Insights
What are the disease risk, burdens, and unmet needs of MASH? What will be the growth opportunities across the 7MM concerning the patient population of MASH?
What is the historical and forecasted MASH patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
Why is the diagnosed prevalent cases of MASH in Japan lower than the US?
Which country has a high patient share for MASH?
Reasons to Buy
Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the MASH prevalent cases in varying geographies over the coming years, along with diagnosed prevalent cases of MASH.
A detailed overview of gender and severity-specific diagnosed prevalent cases of MASH.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Frequently Asked Questions
1. What is the forecast period covered in the report?
The MASH epidemiology report for the 7MM covers the forecast period from 2025 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.
2. Out of all EU4 countries and the UK, which country had the highest population of MASH cases in 2024?
The highest cases of MASH was found in the Germany among EU4 and the UK in 2024.
3. How is epidemiological data collected and analyzed for forecasting purposes?
Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.
4. Out of all 7MM countries, which country had the highest population of MASH cases in 2024?
The highest cases of MASH were found in the US among the 7MM in 2024.
Table of Contents
186 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Epidemiology Overview at a Glance
- 3.1. Patient Share (%) Distribution in 2024
- 3.2. Patient Share (%) Distribution in 2034
- 4. Epidemiology Methodology
- 5. Executive Summary
- 6. Disease Background and Overview
- 6.1.. Introduction
- 6.2.. Risk Factors Associated With MASLD and MASH
- 6.3.. Etiology of MASLD and MASH
- 6.4.. Molecular Pathogenesis
- 6.5.. Symptoms
- 6.6.. Diagnostic Approach
- 6.6.1.. Screening for Advanced Fibrosis-Related
- 6.6.2.. Diagnostic Guidelines
- 6.6.2.1. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis of Nonalcoholic Fatty Liver Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)
- 6.6.3.. Diagnostic Criteria
- 6.6.4.. Diagnostic Algorithm
- 7. Patient Journey
- 8. Epidemiology and Patient Population
- 8.1.. Key Findings
- 8.2.. Assumptions and Rationale: 7MM
- 8.2.1. Prevalent Cases of MASH
- 8.2.2. Diagnosed Prevalent Cases of MASH
- 8.2.3. Gender-specific Diagnosed Prevalent Cases of MASH
- 8.2.4. Severity-specific Diagnosed Prevalent Cases of MASH
- 8.3.. Total Prevalent Cases of MASH in the 7MM
- 8.4.. Total Diagnosed Prevalent Cases of MASH in the 7MM
- 8.5.. The US
- 8.5.1.. Total Prevalent Cases of MASH in the US
- 8.5.2.. Total Diagnosed Prevalent Cases of MASH in the US
- 8.5.3.. Gender-specific Diagnosed Prevalent Cases of MASH in the US
- 8.5.4.. Severity-specific Diagnosed Prevalent Cases of MASH in the US
- 8.6.. EU4 and the UK
- 8.6.1.. Total Prevalent Cases of MASH in EU4 and the UK
- 8.6.2.. Total Diagnosed Prevalent Cases of MASH in EU4 and the UK
- 8.6.3.. Gender-specific Diagnosed Prevalent Cases of MASH in EU4 and the UK
- 8.6.4.. Severity-specific Diagnosed Prevalent Cases of MASH in EU4 and the UK
- 8.7.. Japan
- 8.7.1.. Total Prevalent Cases of MASH in Japan
- 8.7.2.. Total Diagnosed Prevalent Cases of MASH in Japan
- 8.7.3.. Gender-specific Diagnosed Prevalent Cases of MASH in Japan
- 8.7.4.. Severity-specific Diagnosed Prevalent Cases of MASH in Japan
- 9. Key Opinion Leaders’ Views
- 10. Appendix
- 10.1.. Bibliography
- 10.2.. Acronyms and Abbreviations
- 10.3.. Report Methodology
- 11. DelveInsight Capabilities
- 12. Disclaimer
- 13. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
